# Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain

> **NCT00709202** · PHASE2 · COMPLETED · sponsor: **Nathan Kline Institute for Psychiatric Research** · enrollment: 48 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder
- Schizophreniform Disorder
- Bipolar I Disorder
- Bipolar II
- Bipolar NOS(Not Otherwise Specified)
- Psychotic Disorder Not Otherwise Specified
- Autism Spectrum Disorder

## Interventions

- **DRUG:** Betahistine
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT00709202
- **Lead sponsor:** Nathan Kline Institute for Psychiatric Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2016-05
- **Final completion:** 2016-12
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2019-01-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00709202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00709202, "Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00709202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*